This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG . FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310–318.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
Crul M, De Klerk GJ, Swart M, Van’t Veer LJ, De Jong D, Boerrigter L et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor r115777 in advanced cancer. J Clin Oncol 2002; 20: 2726–2735.
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440.
Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2–7.
Fujimaki S, Funato T, Harigae H, Fujiwara J, Kameoka J, Meguro K et al. Quantitative Analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 2002; 48: 811–817.
Litwin C, Leong KG, Zapf R, Sutherland H, Naiman SC, Karsan A . Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia. Am J Hematol 2002; 70: 22–30.
Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885–3891.
Tse KF, Novelli E, Civin CI, Bohmer FD, Small D . Inhibition of FLT-3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001; 15: 1001–1010.
Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H et al. Selective apoptosis of tandemly duplicated FLT-3 transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002; 16: 1535–1540.
Tse KF, Allebach, Levis M, Smith BD, Bohmer FD, Small D . Inhibition of the transforming activity of FLT-3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002; 16: 2027–2036.
Gilliland DG, Griffin JD . Role of FLT3 in leukemia. Curr Opin Hematol 2002; 9: 274–281.
Tomasson MH, Williams IR, Li S, Kutok J, Cain D, Gillessen S et al. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. Blood 2001; 97: 1435–1441.
Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A et al. PKC412—a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15: 17–28.
Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485–1492.
Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al. Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical–laboratory correlative trial. Blood 2001; 97: 3361–3369.
Kurzrock R, Cortes J, Ryback ME, Thibault A, Faderl S, Estey E et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. Blood 2001; 98: 848a (abstract).
Harousseau J-L, Stone R, Thomas X, Lancet J, Arani R, Thibault A et al. Interim results from a phase II study of R1157777 (Zarnestra) in patients with relapsed and refractory acute myelogenous leukemia. J Clin Oncol 2002; 21: 265a (abstract).
Singh SB, Lingham RB . Current progress on farnesyl protein transferase inhibitors. Curr Opin Drug Discov Devel 2002; 5: 225–244.
Pierson AG, Holden SN, Basche M, O’Bryant C, Zakneon S, Statkevich P et al. A phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) sarasar (Ionafarnib, SCH66336), cisplatin C, and gemcitabine (G) in patients with advanced solid tumors. J Clin Oncol 2002; 21: 92a (abstract).
Cortes J, Kurzrock R, O’Brien SG, Thomas D, Faderi S, Garcia-Manero G et al. Phase I study of a farnesyl transferase inhibitor (FTI), BMS-214662, in patients with refractory or relapsed acute leukemias. Blood 200; 98: 594a (abstract).
Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999; 5: 1758–1766.
Banker DE, Radich J, Becker A, Kerkof K, Norwood T, Willman C et al. The t(8;21) translocation is not consistently associated with high Bcl- 2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res 1998; 4: 3051–3062.
Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000; 95: 3929–3938.
O'Brien S, Giles F, Rai K, Andreeff M, Cunningham C, Frankel S et al. Bcl-2 antisense (Genasense) as monotherapy for refractory chronic lymphocytic leukemia. Blood 2001; 98: 772a (abstract).
Marcucci G, Bloomfield CD, Balcerzak SP, Kourlas PJ, Stanley HR, Fingert H et al. Phase I trial of GenasenseTM (G3139, GENTA, INC.), a BCL-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL). Blood 2000; 96: 119a.
Minucci S, Nervi C, Lo CF, Pelicci PG . Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001; 20: 3110–3115.
Wijermans PW, Krulder JW, Huijgens PC, Neve P . Continuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11 (Suppl 1): S19–S23.
Marks PA, Richon VM, Breslow R, Rifkind RA . Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477–483.
Miller CB, Herman JG, Baylin SB, Galm O, Yerian JA, Gore SD . A Phase I dose-descalation trial of combined DNA methyltransferase (MeT)/histone deacetylase (HDAC) inhibition in myeloid malignancies. Blood 2001; 98: 622a (abstract).
Cheson BD, Zwiebel JA, Dancey J, Murgo A . Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 2000; 27: 560–577.
Shtil AA . Emergence of multidrug resistance in leukemia cells during chemotherapy: mechanisms and prevention. J Hematother Stem Cell Res 2002; 11: 231–241.
Shtil AA, Ktitorova OV, Kakpakova ES, Holian O . Differential effects of the MDR1 (multidrug resistance) gene-activating agents on protein kinase C: evidence for redundancy of mechanisms of acquired MDR in leukemia cells. Leuk Lymphoma 2000; 40: 191–195.
Oza AM . Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp 2002; 243: 103–115.
Renes J, de Vries EG, Jansen PL, Muller M . The (patho)physiological functions of the MRP family. Drug Resist Updat 2000; 3: 289–302.
Kostakoglu L . Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet? Clin Lymphoma 2002; 2: 242–248.
Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N . Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002; 16: 1–6.
Steins MB, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834–839.
Yee KWH, O’Farrell AM, Smolich BD, Cherrington JM, Wait CL, Griffith DJ et al. SU5416 and SU5614 inhibit wild-type and activated mutant FLT3 signaling in leukemia cells. Blood 2001; 98: 838a (abstract).
O’Farrell AM, Yuen HA, Louie SG, Schryver B, Wong LM, Hong W et al. Analysis of mechanism of action and biomarkers for kinase inhibitor SU5416 in AML patients. J Clin Oncol 2002; 21: 270a (abstract).
Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21: 499–512.
Mitchell JM, Nuchniyom B, Thorburn J, Frankel AE, Thorburn A . DT-GM, a novel fusion protein for the treatment of AML, induces apoptosis through the extrinsic pathway. Blood 2002; 98: 181b, 4415 (abstract).
Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ . Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002; 8: 1004–1013.
Feldman EJ, Stone RM, Brandwein J, Kalaycio ME, Moore JO, Chopra R et al. Phase III randomized trial of an anti-CD33 monoclonal antibody (HuM195) in combination with chemotherapy compared to chemotherapy alone in adults with refractory or first-relapse acute myeloid leukemia (AML). J Clin Oncol 2002; 21: 261a (abstract).
DeAngelo DJ, Dranoff G, Galinsky I, Hardy S, Mihm Jr M, Webb IJ et al. A phase I study of vaccination with lethally irradiated, autologous myeloblasts engineered by adenoviral mediated gene transfer to secrete human granulocyte–macrophage colony stimulating factor. Blood 2001; 98: 463a (abstract).
Author information
Authors and Affiliations
Additional information
This paper is part of a series of keynote addresses to be published in Leukemia. They were presented at the Acute Leukemia Forum, San Fransisco, 19 April 2002. Supported by an unrestricted educational grant from Immunex.
Rights and permissions
About this article
Cite this article
Stone, R. Induction and postremission therapy: new agents. Leukemia 17, 496–498 (2003). https://doi.org/10.1038/sj.leu.2402864
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402864